Clinical Outcomes in Metastatic Non-small Cell Lung Cancer Harboring BRAF Mutations Treated With Immune Checkpoint Inhibitors

被引：0
|
作者：
Garcia-Illescas, D. [1 ]
Callejo, A. [1 ]
Iranzo, P. [1 ]
Assaf, J. D. [1 ]
Molina, G. [1 ]
Priano, I. [2 ]
Valdivia, A. [1 ]
Pardo, N. [1 ]
Navarro, A. [1 ]
Martinez-Marti, A. [1 ]
Cedres, S. [1 ]
Carbonell, C. [3 ]
Frigola, J. [3 ]
Amat, R. [3 ]
Felip, E. [1 ]
机构：
[1] Vall Hebron Univ Hosp & Inst Oncol VHIO, Med Oncol, Barcelona, Spain
[2] IRCCS Ist Romagnolo Studio Tumori IRST Dino Ama, Dept Med Oncol, Meldola, Italy
[3] Vall Hebron Inst Oncol VHIO, Thorac Cancers Translat Genom Unit, Barcelona, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
BRAF mutation; Immunotherapy; NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.01-07
引用
收藏
页码：S378 / S379
页数：2
相关论文
共 50 条
  • [1] Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring BRAF mutations
    Wang, Haowei
    Cheng, Lei
    Zhao, Chao
    Zhou, Fei
    Jiang, Tao
    Guo, Haoyue
    Shi, Jinpeng
    Chen, Peixin
    Tang, Zhuoran
    Mao, Shiqi
    Jia, Keyi
    Ye, Lingyun
    Cai, Chenlei
    Li, Xuefei
    Chen, Xiaoxia
    Zhou, Caicun
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (02) : 219 - +
  • [2] The efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer harboring driver mutations
    Sakamoto, Hiroaki
    Tanaka, Hisashi
    Shiratori, Toshihiro
    Baba, Keisuke
    Ishioka, Yoshiko
    Itoga, Masamichi
    Taima, Kageaki
    Hasegawa, Yukihiro
    Takanashi, Shingo
    Tasaka, Sadatomo
    [J]. MOLECULAR AND CLINICAL ONCOLOGY, 2019, 10 (06) : 610 - 614
  • [3] Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
    Si, Jinfei
    Hao, Yue
    Wei, Jingwen
    Xiang, Jing
    Xu, Chunwei
    Shen, Qiuping
    Song, Zhengbo
    [J]. BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [4] Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations
    Jinfei Si
    Yue Hao
    Jingwen Wei
    Jing Xiang
    Chunwei Xu
    Qiuping Shen
    Zhengbo Song
    [J]. BMC Pulmonary Medicine, 23
  • [5] The effect of metformin or dipeptidyl peptidase 4 inhibitors on clinical outcomes in metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
    Yang, Jieun
    Kim, Se Hyun
    Jung, Eun Hee
    Kim, Sang-A
    Suh, Koung Jin
    Lee, Ji Yun
    Kim, Ji-Won
    Kim, Jin Won
    Lee, Jeong-Ok
    Kim, Yu Jung
    Lee, Keun-Wook
    Kim, Jee Hyun
    Bang, Soo-Mee
    Lee, Jong Seok
    [J]. THORACIC CANCER, 2023, 14 (01) : 52 - 60
  • [6] Efficacy and safety of immune checkpoint inhibitors in previously treated metastatic non-small cell lung cancer
    Cunha, R.
    Fernandes, M.
    Abreu, S.
    Oliveira, C.
    Dias, J.
    Alves, S.
    Rodrigues, A.
    Oliveira, J.
    Pousa, M. I.
    Soares, M.
    Azevedo, I.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1432 - S1432
  • [7] BRAF inhibitors in metastatic non-small cell lung cancer
    Anguera, Georgia
    Majem, Margarita
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 (02) : 589 - 592
  • [8] Clinical Characteristics and Outcome of Patients with Non-Small Cell Lung Cancer Harboring BRAF Mutations
    Zhang, M.
    Wang, H.
    Ma, Z.
    Zhang, X.
    Li, P.
    Yan, X.
    Zhang, G.
    Niu, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S695 - S695
  • [9] Outcomes with chemotherapy for metastatic non-small cell lung cancer (mNSCLC) in patients previously treated with immune checkpoint inhibitors (CPI).
    Elnair, Radowan
    Chang, Guy Vin
    Powell, Steven Francis
    Sumey, Christopher Joseph
    Bleeker, Jonathan Scott
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Immune checkpoint inhibitors in non-small cell lung cancer
    Eberhardt, Wilfried Ernst Erich
    [J]. ONKOLOGE, 2017, 23 (10): : 838 - 844
12345